Table of Contents Author Guidelines Submit a Manuscript
Volume 2017 (2017), Article ID 7848926, 8 pages
Research Article

Virulence and Antimicrobial Resistance in Campylobacter spp. from a Peruvian Pediatric Cohort

1Instituto de Medicina Tropical, Universidad Peruana Cayetano Heredia, Lima, Peru
2Department of Epidemiology, School of Public Health, University of Texas Health Science Center at Houston, Houston, TX, USA
3ISGlobal, Barcelona Ctr. Int. Health Res. (CRESIB), Hospital Clínic, Universitat de Barcelona, Barcelona, Spain

Correspondence should be addressed to Joaquim Ruiz

Received 14 June 2017; Revised 10 August 2017; Accepted 29 August 2017; Published 9 October 2017

Academic Editor: Giuseppe Comi

Copyright © 2017 Angela Lluque et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


The presence of virulence factors (VFs) and mechanisms of quinolones and macrolide resistance was analyzed in Campylobacter spp. from a pediatric cohort study in Lima. In 149 isolates (39 Campylobacter jejuni and 24 Campylobacter coli from diarrheic cases; 57 C. jejuni and 29 C. coli from controls), the presence of the cdtABC and cadF genes and iam marker was established. Nalidixic acid, ciprofloxacin, erythromycin, and azithromycin susceptibilities were established in 115 isolates and tetracycline-susceptibility was established in 100 isolates. The presence of mutations in the gyrA, parC, and 23S rRNA genes was determined. The cadF gene and all genes from the cdtABC operon were significantly more frequent among C. jejuni (); the iam marker was more frequent in C. coli (). No differences were observed in VFs between cases and controls. Almost all isolates were tetracycline-resistant; nalidixic acid and ciprofloxacin resistance reached levels of 90.4% and 88.7%, respectively. Resistance to macrolides was 13% (C. jejuni 4.3%; C. coli 26.1%). Resistance to ciprofloxacin was related to GyrA Thr86 substitutions, while 13 of 15 macrolide-resistant isolates possessed a 23S rRNA mutation (A2075G). Differences in the presence of VFs and alarming levels of resistance to tested antimicrobial agents were observed among C. jejuni and C. coli.